| Literature DB >> 23910415 |
Milica Radisic1, Karen L Christman.
Abstract
Heart failure after a myocardial infarction continues to be a leading killer in the Western world. Currently, there are no therapies that effectively prevent or reverse the cardiac damage and negative left ventricular remodeling process that follows a myocardial infarction. Because the heart has limited regenerative capacity, there has been considerable effort to develop new therapies that could repair and regenerate the myocardium. Although cell transplantation alone was initially studied, more recently, tissue engineering strategies using biomaterial scaffolds have been explored. In this review, we cover the different approaches to engineering the myocardium, including cardiac patches, which are in vitro-engineered constructs of functional myocardium, and injectable scaffolds, which can either encourage endogenous repair and regeneration or act as vehicles to support the delivery of cells and other therapeutics.Entities:
Keywords: ECM; EHT; ESC; HA; LV; MI; MeHA; PSC; VEGF; bFGF; basic fibroblast growth factor; embryonic stem cell; engineered heart tissue; extracellular matrix; hESC; human embryonic stem cell; hyaluronic acid; iPSC; induced pluripotent stem cell; left ventricular; methacrylated hyaluronic acid; myocardial infarction; pluripotent stem cells; vascular endothelial growth factor
Mesh:
Year: 2013 PMID: 23910415 PMCID: PMC3786696 DOI: 10.1016/j.mayocp.2013.05.003
Source DB: PubMed Journal: Mayo Clin Proc ISSN: 0025-6196 Impact factor: 7.616